FOR RELEASE UPON WEBSITE LAUNCH
IRVINE, Calif. — July 13, 2026 — PathFree Technologies Corporation today announced the launch of its redesigned corporate website, marking an important step in the company's preparation for a potential equity crowdfunding campaign through StartEngine.
The new website provides clinicians, healthcare organizations, strategic partners and prospective investors with a clearer and more structured presentation of PathFree Technologies and its development-stage medical technology, AiMediQ™ powered by datasyteAI™.
The redesign extends beyond visual presentation. PathFree conducted a detailed review of its product descriptions, clinical language, development milestones, intellectual-property references, institutional relationships, security statements and investor communications. The objective was to ensure that the company's public materials accurately reflect its current stage of development and clearly distinguish established facts from development goals, proposed capabilities and activities that remain subject to further evaluation.
"This website represents a more disciplined and transparent presentation of PathFree—what we are building, why the clinical problem matters and what must still be developed and validated," said Dr. Perry M. Brunette, Ph.D., Founder and Chief Executive Officer of PathFree Technologies. "As we prepare for our next stage, we want clinicians, partners and prospective investors to have responsible access to clear, consistent information about the company and its technology."
A clearer presentation of AiMediQ powered by datasyteAI
AiMediQ powered by datasyteAI is being developed as an AI-enabled clinical support and documentation system for time-critical emergency-care workflows, including Code Blue and Advanced Cardiovascular Life Support environments.
The product concept is designed around several of the pressures that clinical teams encounter during emergency response: rapidly changing information, protocol timing, team coordination, fragmented systems and the burden of reconstructing event documentation after care has been delivered.
AiMediQ is intended to function as an adjunctive technology. Its proposed role is to organize relevant information, support workflow awareness and assist documentation while preserving clinician control, professional judgment and institutional protocols.
Product capabilities, specifications, intended use, availability and regulatory status remain subject to continued development, testing, clinical evaluation and applicable regulatory review.
Designed for greater transparency
The redesigned website introduces an expanded and more clearly organized presentation of:
- The clinical problem PathFree is working to address
- The relationship among PathFree Technologies, AiMediQ and datasyteAI
- Product concepts and proposed clinical workflows
- PathFree's development and clinical-evaluation approach
- Publicly documented pilots, intellectual property and institutional relationships
- Security, governance and interoperability objectives
- Leadership, advisors and strategic support
- Clinical-pilot, partnership and investor contact pathways
- Company resources, clinical briefings and press announcements
Conceptual product imagery is identified as such, and development-stage statements are framed to avoid implying established clinical performance, regulatory authorization or commercial availability where those milestones have not been demonstrated.
StartEngine campaign preparation
PathFree is also continuing its preparation for a potential equity crowdfunding campaign through StartEngine. The company is working through the applicable campaign-development, disclosure and review processes before any public offering becomes available.
The timing, structure and availability of any potential offering remain subject to completion of applicable legal, financial, regulatory and platform requirements. PathFree's corporate website will not accept investments. Should an offering proceed, investment information and any opportunity to participate will be made available only through the authorized StartEngine campaign page and its associated offering materials.
"We view this process as an opportunity to establish a stronger foundation for long-term communication," Brunette added. "Our priority is to present PathFree's progress and potential responsibly, without getting ahead of the evidence or the work that remains."
The company expects to provide additional information after the redesigned website is live and its StartEngine preparation reaches the appropriate public stage.
About PathFree Technologies Corporation
PathFree Technologies Corporation is an Irvine, California-based medical technology company developing AiMediQ™ powered by datasyteAI™, a proposed AI-enabled system intended to support time-critical emergency-care workflows.
PathFree's development approach combines clinical workflow design, decision-support concepts, documentation technology and potential hardware integration. The company is focused on creating tools that can assist care teams while preserving clinician oversight, institutional governance and existing standards of care.
For additional company information, visit pathfree.com.
Media and corporate inquiries
Dr. Perry M. Brunette, Ph.D.
Founder and Chief Executive Officer
PathFree Technologies Corporation
Email: perry@pathfree.com
Website: pathfree.com
Development-stage product notice
AiMediQ powered by datasyteAI is a development-stage product. References to proposed features, functionality, integrations, security capabilities, clinical applications or potential benefits describe development objectives and should not be interpreted as representations of commercial availability, regulatory clearance or approval, validated clinical performance, or demonstrated patient outcomes. No statement in this announcement should be interpreted as medical advice or as a substitute for clinician judgment.
Securities notice for use before Form C filing
PathFree Technologies Corporation is considering a potential securities offering. No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy securities can be accepted, and no part of the purchase price can be received, until PathFree Technologies determines the exemption under which an offering may be conducted and, where applicable, the relevant filing, disclosure or qualification requirements have been satisfied. Any indication of interest involves no obligation or commitment of any kind.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities. Any potential offering will be made only through authorized offering materials and the applicable intermediary platform.
Forward-looking statements
This announcement contains forward-looking statements, including statements concerning PathFree's development plans, product concepts, website launch, clinical-evaluation activities, regulatory strategy, potential partnerships, commercialization objectives and preparation for a possible crowdfunding offering. These statements are based on current expectations and involve risks, uncertainties and assumptions. Actual activities, timelines and results may differ materially. PathFree undertakes no obligation to update forward-looking statements except as required by applicable law.